Topotecan Episcleral Plaque for Treatment of Retinoblastoma
Status:
Recruiting
Trial end date:
2023-10-14
Target enrollment:
Participant gender:
Summary
This single-arm, non-randomized, dose escalation phase I clinical trial will assess primarily
the safety and secondarily the efficacy of episcleral topotecan in patients with active de
novo or recurrent intraocular retinoblastoma in at least one eye following completion of
first-line therapy.